212 related articles for article (PubMed ID: 17098043)
1. Sirolimus attenuates chronic allograft nephropathy in an experimental rat kidney transplantation model.
Savikko J; von Willebrand E
Transplant Proc; 2006 Oct; 38(8):2699-700. PubMed ID: 17098043
[TBL] [Abstract][Full Text] [Related]
2. Early short-term platelet-derived growth factor inhibition prevents the development of chronic allograft nephropathy in experimental rat kidney transplantation.
Savikko J; Rintala J; von Willebrand E
Transplant Proc; 2006 Dec; 38(10):3231-2. PubMed ID: 17175231
[TBL] [Abstract][Full Text] [Related]
3. The effect of leflunomide analogue FK778 on development of chronic rat renal allograft rejection and transforming growth factor-BETA expression.
Rintala JM; Savikko J; Rintala SE; von Willebrand E
Transplant Proc; 2006 Dec; 38(10):3239-40. PubMed ID: 17175234
[TBL] [Abstract][Full Text] [Related]
4. FK778 ameliorates post-transplant expression of fibrogenic growth factors and development of chronic rejection changes in rat kidney allografts.
Rintala JM; Savikko J; Rintala SE; von Willebrand E
Nephrol Dial Transplant; 2008 Nov; 23(11):3446-55. PubMed ID: 18558624
[TBL] [Abstract][Full Text] [Related]
5. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy.
Savikko J; Taskinen E; Von Willebrand E
Transplantation; 2003 Apr; 75(8):1147-53. PubMed ID: 12717194
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor (VEGF) ligand and receptor induction in rat renal allograft rejection.
Rintala SE; Savikko J; Rintala JM; von Willebrand E
Transplant Proc; 2006 Dec; 38(10):3236-8. PubMed ID: 17175233
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus inhibits lymphangiogenesis in rat renal allografts, a novel mechanism to prevent chronic kidney allograft injury.
Palin NK; Savikko J; Koskinen PK
Transpl Int; 2013 Feb; 26(2):195-205. PubMed ID: 23167600
[TBL] [Abstract][Full Text] [Related]
8. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
[TBL] [Abstract][Full Text] [Related]
9. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients.
Stallone G; Di Paolo S; Schena A; Infante B; Grandaliano G; Battaglia M; Gesualdo L; Schena FP
Transplantation; 2003 Apr; 75(7):998-1003. PubMed ID: 12698087
[TBL] [Abstract][Full Text] [Related]
10. Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy.
Savikko J; Rintala JM; Rintala SE; Koskinen PK; von Willebrand E
Nephrol Dial Transplant; 2011 Sep; 26(9):3026-32. PubMed ID: 21285128
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin and cyclosporine have different effects on expression of Ang-1 and Ang-2 and Tie2 in rat renal allograft with chronic allograft nephropathy.
Ma X; Lu YP; Yang L; Song J; Luo GH; Shi YJ; Li YP
Transplant Proc; 2008 Oct; 40(8):2804-7. PubMed ID: 18929866
[TBL] [Abstract][Full Text] [Related]
12. The effect of sirolimus in the development of chronic allograft nephropathy.
Gürkan A; Kaçar S; Erdoğdu U; Varilsüha C; Kandemir G; Karaca C; Akman F
Transplant Proc; 2008; 40(1):114-6. PubMed ID: 18261561
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
Roos M; Liu S; Strobl M; Schmaderer C; Baumann M; Heemann U; Lutz J
Transplant Proc; 2008 Dec; 40(10):3731-6. PubMed ID: 19100477
[TBL] [Abstract][Full Text] [Related]
14. Is sirolimus a safe alternative to reduce or eliminate calcineurin inhibitors in chronic allograft nephropathy in kidney transplantation?
Lai WJ; Chiang YJ; Chen Y; Chu SH
Transplant Proc; 2004 Sep; 36(7):2056-7. PubMed ID: 15518744
[TBL] [Abstract][Full Text] [Related]
15. The effect of FK778 on acute rat renal allograft rejection and expression of platelet-derived growth factor and transforming growth factor-beta.
Rintala JM; Savikko J; Rintala SE; von Willebrand E
Transplant Proc; 2006 Oct; 38(8):2719-21. PubMed ID: 17098049
[TBL] [Abstract][Full Text] [Related]
16. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
17. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
Krüger B; Fischereder M; Jauch KW; Graeb C; Hoffmann U; Böger CA; Banas B; Obed A; Schlitt HJ; Krämer BK
Transplant Proc; 2007 Mar; 39(2):518-21. PubMed ID: 17362772
[TBL] [Abstract][Full Text] [Related]
18. Detection of citrate synthase autoantibodies in rats with chronic allograft nephropathy.
Zhang LY; Lu YP; Yang L; Luo GH; Song J; Li YP
Transplant Proc; 2009 Dec; 41(10):4366-8. PubMed ID: 20005400
[TBL] [Abstract][Full Text] [Related]
19. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
Boratyńska M; Banasik M; Watorek E; Falkiewicz K; Patrzałek D; Szyber P; Klinger M
Transplant Proc; 2006; 38(1):101-4. PubMed ID: 16504675
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
